COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,789 Articles (22,946 medRxiv, 8,843 bioRxiv)

Most recent first Previous |  Page 1382: Articles 13811-13820  | Next

Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection
Ryan, F. J., Hope, C. M., Masavuli, M. G., Lynn, M. A., Mekonnen, Z. A., Yeow, A. E. L., Valtanen, P. G., Al-Delfi, Z., Gummow, J. A., Ferguson, C., O'Connor, S., Reddi, B., Shaw, D., Kok-Lim, C., Gleadle, J. M., Beard, M. R., Barry, S. C., Grubor-Bauk, B., Lynn, D. J.
10.1101/2021.07.30.21261234 — Posted: 2021-08-03 Discussion: Onsite
High parental vaccine motivation at a neighborhood-based vaccine and testing site serving a predominantly Latinx community
Naso, J., Rojas, S., Peng, J., Marquez, C., Contreras, M., Castellanos, E., Rojas, S., Rubio, L., Jones, D., Jacobo, J., Black, D., Tulier-Laiwa, V., Martinez, J., Chamie, G., Pilarowski, G., Derisi, J., Havlir, D., Petersen, M.
10.1101/2021.07.30.21261274 — Posted: 2021-08-03
SARS-CoV-2 fears green: the chlorophyll catabolite Pheophorbide a is a potent antiviral
Jimenez-Aleman, G. H., Castro, V., Longdaitsbehere, A., Gutierrez-Rodriguez, M., Garaigorta, U., Gastaminza, P., Solano, R.
10.1101/2021.07.31.454592 — Posted: 2021-08-02
Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses
Ndeupen, S., Bouteau, A., Herbst, C., Qin, Z., Hutchins, Z., Kurup, D., Diba, L. Z., Igyarto, B.
10.1101/2021.08.01.454662 — Posted: 2021-08-02
Analysis of B-cell receptor repertoires in COVID-19 patients using deep embedded representations of protein sequences
Kim, I., Byun, S. Y., Kim, S., Choi, S., Noh, J., Chung, J., Kim, B. G.
10.1101/2021.08.02.454701 — Posted: 2021-08-02
Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein
Tan, Z. W., Tee, W.-V., Samsudin, F., Guarnera, E., Bond, P. J., Berezovsky, I. N.
10.1101/2021.08.01.454696 — Posted: 2021-08-02
Regional Variant Analysis of Spike Glycoprotein Mutations of SARS-CoV-2 and Its Implications in COVID-19 Pandemic Control
Punnoth Poonkuzhi, N., Elayadeth-Meethal, M., Ollakkot, S., UK, I., Saheer Kuruniyan, M.
10.1101/2021.08.02.454771 — Posted: 2021-08-02
The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin α5β1 and NF-κB
Robles, J. P., Zamora, M., Martinez de la Escalera, G., Clapp, C.
10.1101/2021.08.01.454605 — Posted: 2021-08-02 Discussion: Onsite
Existing human mobility data sources poorly predicted the spatial spread of SARS-CoV-2 in Madagascar
Ramiadantsoa, T., Metcalf, C. J. E., Raherinandrasana, A. H., Randrianarisoa, S., Rice, B. L., Wesolowski, A., Randriatsarafara, F. M., Rasambainarivo, F.
10.1101/2021.07.30.21261392 — Posted: 2021-08-02
Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis
Burn, E., Li, X., Delmestri, A., Jones, N., Duarte-Salles, T., Reyes, C., Martinez-Hernandez, E., Marti, E., Verhamme, K. M., Rijnbeek, P. R., Strauss, V. Y., Prieto-Alhambra, D.
10.1101/2021.07.29.21261348 — Posted: 2021-08-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).